Lista de obras -

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

artículo científico publicado en 2015

Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement ⬇️

artículo científico publicado el 1 de mayo de 2012

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

artículo científico publicado en 2015

Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy

artículo científico publicado en 2017

Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

artículo científico publicado en 2018

Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance

artículo científico publicado en 2016

Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer

artículo científico publicado en 2014

Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients

artículo científico publicado en 2012

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

artículo científico publicado en 2015

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

artículo científico publicado en 2018

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

artículo científico publicado en 2015

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer ⬇️

artículo científico publicado el 31 de mayo de 2012

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

artículo científico publicado en 2017

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

artículo científico publicado en 2017

Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives

artículo científico publicado en 2009

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario ⬇️

article

IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity

artículo científico publicado en 2013

Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care

artículo científico publicado en 2006

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study ⬇️

artículo científico publicado el 22 de noviembre de 2011

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

artículo científico publicado en 2017

Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

artículo científico publicado en 2016

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

artículo científico publicado en 2017

NSCLC and HER2: between lights and shadows

artículo científico

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

artículo científico publicado en 2016

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

scientific article published on 30 January 2020

Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy

artículo científico publicado en 2017

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

artículo científico publicado en 2020

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.

artículo científico publicado en 2017

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

scientific article published on 16 March 2016

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

artículo científico publicado en 2017

The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population

artículo científico publicado en 2013

Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days)

scientific article published on 01 September 2020

Lista de obras de

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement ⬇️

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy

Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance

Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer

Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer ⬇️

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario ⬇️

IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity

Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study ⬇️

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

NSCLC and HER2: between lights and shadows

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population

Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and &#39;0-7-21&#39; Radiotherapy Regimen (24 Gy/3 fractions/21 days)

Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days)